| Symbol | SRPT |
|---|---|
| Name | SAREPTA THERAPEUTICS, INC. |
| Sector | HEALTH CARE |
| Region | North America |
| Industry | Biotechnology: Pharmaceutical Preparations |
| Address | 215 FIRST STREET,SUITE 415, CAMBRIDGE, Massachusetts, 02142, United States |
| Telephone | +1 617 274-4000 |
| Fax | — |
| — | |
| Website | https://www.sarepta.com |
| Incorporation | UNDEFINED |
| Incorporated On | — |
| Employees | — |
| Fiscal Year | — |
| Public Since | — |
| Exchanges | NASDAQ |
| Auditor | — |
| Audit Status | NOT PROVIDED |
| Reporting Status | — |
| CIK | 0000873303 |
| Description | Sarepta Therapeutics is a biotechnology company focused on treating rare, infectious, and other diseases. It targets a broad range of diseases while focusing on the rapid development of its drug candidates. Sareptas strategy involves proprietary RNA-targeted technology platforms to be used for developing novel pharmaceutical products to treat a broad range of diseases and address key unmet medical needs. The company uses third-party contractors to manufacture its product candidates. Most of Sareptas product candidates are at an early stage of development. Additional info from NASDAQ: |
2026-06-30 20:25
Sarepta Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Read more
2026-06-30 12:30
Sarepta Announces FDA Acceptance of sNDAs for AMONDYS 45® and VYONDYS 53®
Read more
2026-06-06 00:11
Boor Kathryn Jean 🟢 acquired 16.9K shares of Sarepta Therapeutics, Inc. (SRPT) Transaction Date: Jun 04, 2026 | Filing ID: 260263
Read more
2026-06-06 00:10
Mayo Stephen 🟢 acquired 16.9K shares of Sarepta Therapeutics, Inc. (SRPT) Transaction Date: Jun 04, 2026 | Filing ID: 260261
Read more
2026-06-06 00:09
Wigzell Hans Lennart Rudolf 🟢 acquired 16.9K shares of Sarepta Therapeutics, Inc. (SRPT) Transaction Date: Jun 04, 2026 | Filing ID: 260259
Read more
2026-06-06 00:08
BEHRENS M KATHLEEN 🟢 acquired 16.9K shares of Sarepta Therapeutics, Inc. (SRPT) Transaction Date: Jun 04, 2026 | Filing ID: 260257
Read more
2026-06-06 00:07
Connelly Deirdre P 🟢 acquired 16.9K shares of Sarepta Therapeutics, Inc. (SRPT) Transaction Date: Jun 04, 2026 | Filing ID: 260255
Read more
2026-06-06 00:04
Nicaise Claude 🟢 acquired 16.9K shares of Sarepta Therapeutics, Inc. (SRPT) Transaction Date: Jun 04, 2026 | Filing ID: 260250
Read more
2026-06-06 00:02
Chambers Michael Andrew 🟢 acquired 16.9K shares of Sarepta Therapeutics, Inc. (SRPT) Transaction Date: Jun 04, 2026 | Filing ID: 260246
Read more
2026-06-06 00:02
Barry Richard 🟢 acquired 16.9K shares of Sarepta Therapeutics, Inc. (SRPT) Transaction Date: Jun 04, 2026 | Filing ID: 260245
Read more| Trial ID | Title | Phase | Indication | Status | Start Date | Completion Date | Source |
|---|---|---|---|---|---|---|---|
| NCT07542314 | Study to Evaluate the Safety and Effectiveness of ELEVIDYS in Participants With… | Phase4 | Duchenne Muscular Dystrophy | Not_Yet_Recruiting | 2026-07-31 | 2027-03-31 | ClinicalTrials.gov |
| NCT07542314 | Study to Evaluate the Safety and Effectiveness of ELEVIDYS in Participants With… | Phase4 | Duchenne Muscular Dystrophy | Not_Yet_Recruiting | 2026-07-31 | 2027-03-31 | ClinicalTrials.gov |
| NCT07536061 | A First-in-human Study of the Effects of SRP-1005 in Participants With Huntingt… | Phase1 | Huntington's Disease | Recruiting | 2026-05-12 | 2027-11-30 | ClinicalTrials.gov |
| NCT07536061 | A First-in-human Study of the Effects of SRP-1005 in Participants With Huntingt… | Phase1 | Huntington's Disease | Recruiting | 2026-05-12 | 2027-11-30 | ClinicalTrials.gov |
| NCT06952686 | A Study of SRP-9005 in Limb Girdle Muscular Dystrophy Type 2C/R5 Pediatric and … | Phase3 | Muscular Dystrophies, Limb-Girdle | Withdrawn | 2025-06-30 | 2032-03-30 | ClinicalTrials.gov |
| NCT06952686 | A Study of SRP-9005 in Limb Girdle Muscular Dystrophy Type 2C/R5 Pediatric and … | Phase3 | Muscular Dystrophies, Limb-Girdle | Withdrawn | 2025-06-30 | 2032-03-30 | ClinicalTrials.gov |
| NCT06747273 | Study to Evaluate the Safety, Tolerability, and Efficacy of SRP-9004 Administer… | Phase1 | Limb Girdle Muscular Dystrophy | Terminated | 2025-01-09 | 2025-06-18 | ClinicalTrials.gov |
| NCT06747273 | Study to Evaluate the Safety, Tolerability, and Efficacy of SRP-9004 Administer… | Phase1 | Limb Girdle Muscular Dystrophy | Terminated | 2025-01-09 | 2025-06-18 | ClinicalTrials.gov |
| NCT06597656 | A Gene Transfer Therapy to Evaluate the Safety and Efficacy of Delandistrogene … | Phase1 | Duchenne Muscular Dystrophy | Terminated | 2024-09-18 | 2025-08-05 | ClinicalTrials.gov |
| NCT06597656 | A Gene Transfer Therapy to Evaluate the Safety and Efficacy of Delandistrogene … | Phase1 | Duchenne Muscular Dystrophy | Terminated | 2024-09-18 | 2025-08-05 | ClinicalTrials.gov |
| NCT06270719 | An Observational Study Comparing Delandistrogene Moxeparvovec (ELEVIDYS) With S… | — | Duchenne Muscular Dystrophy | Enrolling_By_Invitation | 2024-02-07 | 2038-12-31 | ClinicalTrials.gov |
| NCT06270719 | An Observational Study Comparing Delandistrogene Moxeparvovec (ELEVIDYS) With S… | — | Duchenne Muscular Dystrophy | Enrolling_By_Invitation | 2024-02-07 | 2038-12-31 | ClinicalTrials.gov |
| NCT06241950 | A Gene Transfer Therapy Study to Evaluate the Safety and Efficacy of Delandistr… | Phase1 | Duchenne Muscular Dystrophy | Terminated | 2024-01-29 | 2025-10-10 | ClinicalTrials.gov |
| NCT06241950 | A Gene Transfer Therapy Study to Evaluate the Safety and Efficacy of Delandistr… | Phase1 | Duchenne Muscular Dystrophy | Terminated | 2024-01-29 | 2025-10-10 | ClinicalTrials.gov |
| NCT06246513 | A Trial to Learn More About an Experimental Gene Therapy Called Bidridistrogene… | Phase3 | Limb-girdle Muscular Dystrophy | Active_Not_Recruiting | 2024-01-15 | 2029-11-30 | ClinicalTrials.gov |
| NCT06246513 | A Trial to Learn More About an Experimental Gene Therapy Called Bidridistrogene… | Phase3 | Limb-girdle Muscular Dystrophy | Active_Not_Recruiting | 2024-01-15 | 2029-11-30 | ClinicalTrials.gov |
| NCT06128564 | A Gene Delivery Study to Evaluate the Safety and Expression of Delandistrogene … | Phase2 | Duchenne Muscular Dystrophy | Active_Not_Recruiting | 2023-11-29 | 2030-02-18 | ClinicalTrials.gov |
| NCT06128564 | A Gene Delivery Study to Evaluate the Safety and Expression of Delandistrogene … | Phase2 | Duchenne Muscular Dystrophy | Active_Not_Recruiting | 2023-11-29 | 2030-02-18 | ClinicalTrials.gov |
| NCT05967351 | A Long-term Follow-up Study of Participants Who Received Delandistrogene Moxepa… | Phase3 | Duchenne Muscular Dystrophy | Enrolling_By_Invitation | 2023-09-27 | 2033-10-31 | ClinicalTrials.gov |
| NCT05967351 | A Long-term Follow-up Study of Participants Who Received Delandistrogene Moxepa… | Phase3 | Duchenne Muscular Dystrophy | Enrolling_By_Invitation | 2023-09-27 | 2033-10-31 | ClinicalTrials.gov |
| NCT05881408 | A Gene Transfer Therapy Study to Evaluate the Safety and Efficacy of Delandistr… | Phase3 | Duchenne Muscular Dystrophy | Active_Not_Recruiting | 2023-05-31 | 2028-06-30 | ClinicalTrials.gov |
| NCT05881408 | A Gene Transfer Therapy Study to Evaluate the Safety and Efficacy of Delandistr… | Phase3 | Duchenne Muscular Dystrophy | Active_Not_Recruiting | 2023-05-31 | 2028-06-30 | ClinicalTrials.gov |
| NCT05906251 | A Gene Transfer Study to Evaluate the Safety, Tolerability and Efficacy of SRP-… | Phase1 | Limb Girdle Muscular Dystrophy | Terminated | 2023-05-22 | 2025-06-13 | ClinicalTrials.gov |
| NCT05906251 | A Gene Transfer Study to Evaluate the Safety, Tolerability and Efficacy of SRP-… | Phase1 | Limb Girdle Muscular Dystrophy | Terminated | 2023-05-22 | 2025-06-13 | ClinicalTrials.gov |
| NCT05876780 | A Gene Transfer Single Dose Study to Evaluate the Safety, Tolerability and Effi… | Phase1 | Limb Girdle Muscular Dystrophy | Active_Not_Recruiting | 2022-12-19 | 2028-08-28 | ClinicalTrials.gov |
| NCT05876780 | A Gene Transfer Single Dose Study to Evaluate the Safety, Tolerability and Effi… | Phase1 | Limb Girdle Muscular Dystrophy | Active_Not_Recruiting | 2022-12-19 | 2028-08-28 | ClinicalTrials.gov |
| NCT06581887 | Defining Outcome Measures for Behavioural and Emotional Problems in Dystrophino… | — | DMD | Recruiting | 2022-09-13 | 2024-12-31 | ClinicalTrials.gov |
| NCT06581887 | Defining Outcome Measures for Behavioural and Emotional Problems in Dystrophino… | — | DMD | Recruiting | 2022-09-13 | 2024-12-31 | ClinicalTrials.gov |
| NCT05096221 | A Gene Transfer Therapy Study to Evaluate the Safety and Efficacy of Delandistr… | Phase3 | Duchenne Muscular Dystrophy | Completed | 2021-10-27 | 2024-10-25 | ClinicalTrials.gov |
| NCT05096221 | A Gene Transfer Therapy Study to Evaluate the Safety and Efficacy of Delandistr… | Phase3 | Duchenne Muscular Dystrophy | Completed | 2021-10-27 | 2024-10-25 | ClinicalTrials.gov |
| NCT04475926 | A Study of the Natural History of Participants With LGMD2E/R4, LGMD2D/R3, LGMD2… | — | Limb-girdle Muscular Dystrophy | Active_Not_Recruiting | 2021-04-22 | 2030-09-05 | ClinicalTrials.gov |
| NCT04475926 | A Study of the Natural History of Participants With LGMD2E/R4, LGMD2D/R3, LGMD2… | — | Limb-girdle Muscular Dystrophy | Active_Not_Recruiting | 2021-04-22 | 2030-09-05 | ClinicalTrials.gov |
| NCT04626674 | A Gene Transfer Therapy Study to Evaluate the Safety of and Expression From Del… | Phase1 | Duchenne Muscular Dystrophy | Recruiting | 2020-11-23 | 2028-02-29 | ClinicalTrials.gov |
| NCT04626674 | A Gene Transfer Therapy Study to Evaluate the Safety of and Expression From Del… | Phase1 | Duchenne Muscular Dystrophy | Recruiting | 2020-11-23 | 2028-02-29 | ClinicalTrials.gov |
| NCT04708314 | An Open-Label Study of Golodirsen in Non-Ambulant Patients With Duchenne Muscul… | Phase4 | Duchenne Muscular Dystrophy | Terminated | 2020-10-31 | 2021-05-13 | ClinicalTrials.gov |
| NCT04708314 | An Open-Label Study of Golodirsen in Non-Ambulant Patients With Duchenne Muscul… | Phase4 | Duchenne Muscular Dystrophy | Terminated | 2020-10-31 | 2021-05-13 | ClinicalTrials.gov |
| NCT03992430 | A Study to Compare Safety and Efficacy of High Doses of Eteplirsen in Participa… | Phase3 | Muscular Dystrophy, Duchenne | Active_Not_Recruiting | 2020-07-13 | 2026-10-31 | ClinicalTrials.gov |
| NCT03992430 | A Study to Compare Safety and Efficacy of High Doses of Eteplirsen in Participa… | Phase3 | Muscular Dystrophy, Duchenne | Active_Not_Recruiting | 2020-07-13 | 2026-10-31 | ClinicalTrials.gov |
| NCT04179409 | A 48-Week, Open Label, Study to Evaluate the Efficacy and Safety of AMONDYS 45,… | Phase2 | Duchenne Muscular Dystrophy | Completed | 2020-02-18 | 2023-09-01 | ClinicalTrials.gov |
| NCT04179409 | A 48-Week, Open Label, Study to Evaluate the Efficacy and Safety of AMONDYS 45,… | Phase2 | Duchenne Muscular Dystrophy | Completed | 2020-02-18 | 2023-09-01 | ClinicalTrials.gov |
| NCT04004065 | Two-Part Study for Dose Determination of Vesleteplirsen (SRP-5051) (Part A), Th… | Phase2 | Duchenne Muscular Dystrophy | Terminated | 2019-06-26 | 2025-02-07 | ClinicalTrials.gov |
| NCT03985878 | A Study to Evaluate Safety, Tolerability, and Efficacy of Eteplirsen in Partici… | Phase2 | Duchenne Muscular Dystrophy | Terminated | 2019-06-26 | 2022-08-31 | ClinicalTrials.gov |
| NCT04004065 | Two-Part Study for Dose Determination of Vesleteplirsen (SRP-5051) (Part A), Th… | Phase2 | Duchenne Muscular Dystrophy | Terminated | 2019-06-26 | 2025-02-07 | ClinicalTrials.gov |
| NCT03985878 | A Study to Evaluate Safety, Tolerability, and Efficacy of Eteplirsen in Partici… | Phase2 | Duchenne Muscular Dystrophy | Terminated | 2019-06-26 | 2022-08-31 | ClinicalTrials.gov |
| NCT06606340 | A Long-term Observational Study Evaluating Eteplirsen, Golodirsen, or Casimerse… | — | Duchenne Muscular Dystrophy | Enrolling_By_Invitation | 2019-01-07 | 2033-12-31 | ClinicalTrials.gov |
| NCT06606340 | A Long-term Observational Study Evaluating Eteplirsen, Golodirsen, or Casimerse… | — | Duchenne Muscular Dystrophy | Enrolling_By_Invitation | 2019-01-07 | 2033-12-31 | ClinicalTrials.gov |
| NCT03675126 | An Open-Label Extension Study for Patients With Duchenne Muscular Dystrophy Who… | Phase1 | Muscular Dystrophy, Duchenne | Terminated | 2018-12-19 | 2021-08-25 | ClinicalTrials.gov |
| NCT03675126 | An Open-Label Extension Study for Patients With Duchenne Muscular Dystrophy Who… | Phase1 | Muscular Dystrophy, Duchenne | Terminated | 2018-12-19 | 2021-08-25 | ClinicalTrials.gov |
| NCT03769116 | A Randomized, Double-blind, Placebo-controlled Study of Delandistrogene Moxepar… | Phase1 | Muscular Dystrophy, Duchenne | Completed | 2018-12-05 | 2023-08-16 | ClinicalTrials.gov |
| NCT03769116 | A Randomized, Double-blind, Placebo-controlled Study of Delandistrogene Moxepar… | Phase1 | Muscular Dystrophy, Duchenne | Completed | 2018-12-05 | 2023-08-16 | ClinicalTrials.gov |
| NCT03652259 | Gene Delivery Clinical Trial of SRP-9003 (Bidridistrogene Xeboparvovec) for Par… | Phase1 | Limb-Girdle Muscular Dystrophy, Type 2E | Terminated | 2018-10-27 | 2025-01-14 | ClinicalTrials.gov |
| NCT03652259 | Gene Delivery Clinical Trial of SRP-9003 (Bidridistrogene Xeboparvovec) for Par… | Phase1 | Limb-Girdle Muscular Dystrophy, Type 2E | Terminated | 2018-10-27 | 2025-01-14 | ClinicalTrials.gov |
| NCT03655223 | Early Check: Expanded Screening in Newborns | — | Spinal Muscular Atrophy | Active_Not_Recruiting | 2018-10-15 | 2026-12-31 | ClinicalTrials.gov |
| NCT03655223 | Early Check: Expanded Screening in Newborns | — | Spinal Muscular Atrophy | Active_Not_Recruiting | 2018-10-15 | 2026-12-31 | ClinicalTrials.gov |
| NCT03680365 | Your Voice; Impact of Duchenne Muscular Dystrophy (DMD) on the Lives of Families | — | Duchenne Muscular Dystrophy | Completed | 2018-09-20 | 2019-03-15 | ClinicalTrials.gov |
| NCT03680365 | Your Voice; Impact of Duchenne Muscular Dystrophy (DMD) on the Lives of Families | — | Duchenne Muscular Dystrophy | Completed | 2018-09-20 | 2019-03-15 | ClinicalTrials.gov |
| NCT03532542 | An Extension Study to Evaluate Casimersen or Golodirsen in Patients With Duchen… | Phase3 | Duchenne Muscular Dystrophy | Terminated | 2018-08-02 | 2023-07-26 | ClinicalTrials.gov |
| NCT03532542 | An Extension Study to Evaluate Casimersen or Golodirsen in Patients With Duchen… | Phase3 | Duchenne Muscular Dystrophy | Terminated | 2018-08-02 | 2023-07-26 | ClinicalTrials.gov |
| NCT03375255 | A Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of a Single … | Phase1 | Muscular Dystrophy, Duchenne | Completed | 2018-02-05 | 2019-08-19 | ClinicalTrials.gov |
| NCT03375255 | A Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of a Single … | Phase1 | Muscular Dystrophy, Duchenne | Completed | 2018-02-05 | 2019-08-19 | ClinicalTrials.gov |
| NCT03375164 | A Gene Transfer Therapy Study to Evaluate the Safety of Delandistrogene Moxepar… | Phase1 | Duchenne Muscular Dystrophy | Completed | 2018-01-04 | 2023-04-25 | ClinicalTrials.gov |
| NCT03375164 | A Gene Transfer Therapy Study to Evaluate the Safety of Delandistrogene Moxepar… | Phase1 | Duchenne Muscular Dystrophy | Completed | 2018-01-04 | 2023-04-25 | ClinicalTrials.gov |
| NCT03218995 | Study of Eteplirsen in Young Participants With Duchenne Muscular Dystrophy (DMD… | Phase2 | Duchenne Muscular Dystrophy | Completed | 2017-08-16 | 2021-03-10 | ClinicalTrials.gov |
| NCT03218995 | Study of Eteplirsen in Young Participants With Duchenne Muscular Dystrophy (DMD… | Phase2 | Duchenne Muscular Dystrophy | Completed | 2017-08-16 | 2021-03-10 | ClinicalTrials.gov |
| NCT02500381 | Study of SRP-4045 (Casimersen) and SRP-4053 (Golodirsen) in Participants With D… | Phase3 | Duchenne Muscular Dystrophy | Completed | 2016-09-28 | 2025-10-16 | ClinicalTrials.gov |
| NCT02500381 | Study of SRP-4045 (Casimersen) and SRP-4053 (Golodirsen) in Participants With D… | Phase3 | Duchenne Muscular Dystrophy | Completed | 2016-09-28 | 2025-10-16 | ClinicalTrials.gov |
| NCT02710500 | rAAVrh74.MHCK7.DYSF.DV for Treatment of Dysferlinopathies | Phase1 | Dysferlinopathy | Completed | 2016-03-01 | 2019-07-01 | ClinicalTrials.gov |
| NCT02710500 | rAAVrh74.MHCK7.DYSF.DV for Treatment of Dysferlinopathies | Phase1 | Dysferlinopathy | Completed | 2016-03-01 | 2019-07-01 | ClinicalTrials.gov |
| NCT02530905 | Dose-Titration and Open-label Extension Study of SRP-4045 in Advanced Stage Duc… | Phase1 | Duchenne Muscular Dystrophy | Completed | 2015-10-08 | 2018-10-03 | ClinicalTrials.gov |
| NCT02530905 | Dose-Titration and Open-label Extension Study of SRP-4045 in Advanced Stage Duc… | Phase1 | Duchenne Muscular Dystrophy | Completed | 2015-10-08 | 2018-10-03 | ClinicalTrials.gov |
| NCT02420379 | Safety Study of Eteplirsen to Treat Early Stage Duchenne Muscular Dystrophy | Phase2 | Duchenne Muscular Dystrophy (DMD) | Completed | 2015-06-30 | 2018-12-17 | ClinicalTrials.gov |
| NCT02420379 | Safety Study of Eteplirsen to Treat Early Stage Duchenne Muscular Dystrophy | Phase2 | Duchenne Muscular Dystrophy (DMD) | Completed | 2015-06-30 | 2018-12-17 | ClinicalTrials.gov |
| NCT01976091 | A Gene Transfer Therapy Study to Evaluate the Safety of SRP-9004 (Patidistrogen… | Phase1 | Limb-Girdle Muscular Dystrophy, Type 2D | Completed | 2015-02-01 | 2019-03-14 | ClinicalTrials.gov |
| NCT01976091 | A Gene Transfer Therapy Study to Evaluate the Safety of SRP-9004 (Patidistrogen… | Phase1 | Limb-Girdle Muscular Dystrophy, Type 2D | Completed | 2015-02-01 | 2019-03-14 | ClinicalTrials.gov |
| NCT02310906 | Phase I/II Study of SRP-4053 in DMD Patients | Phase1 | Duchenne Muscular Dystrophy | Completed | 2015-01-13 | 2019-03-25 | ClinicalTrials.gov |
| NCT02310906 | Phase I/II Study of SRP-4053 in DMD Patients | Phase1 | Duchenne Muscular Dystrophy | Completed | 2015-01-13 | 2019-03-25 | ClinicalTrials.gov |
| NCT02255552 | Study of Eteplirsen in DMD Patients | Phase3 | Duchenne Muscular Dystrophy (DMD) | Completed | 2014-11-17 | 2019-06-14 | ClinicalTrials.gov |
| NCT02255552 | Study of Eteplirsen in DMD Patients | Phase3 | Duchenne Muscular Dystrophy (DMD) | Completed | 2014-11-17 | 2019-06-14 | ClinicalTrials.gov |
| NCT02286947 | Safety Study of Eteplirsen to Treat Advanced Stage Duchenne Muscular Dystrophy | Phase2 | Muscular Dystrophy, Duchenne | Completed | 2014-11-01 | 2018-03-23 | ClinicalTrials.gov |
| NCT02286947 | Safety Study of Eteplirsen to Treat Advanced Stage Duchenne Muscular Dystrophy | Phase2 | Muscular Dystrophy, Duchenne | Completed | 2014-11-01 | 2018-03-23 | ClinicalTrials.gov |
| NCT01566877 | A Study to Assess the Safety, Tolerability and Pharmacokinetics of AVI-7288 in … | Phase1 | Marburg Hemorrhagic Fever | Completed | 2013-05-01 | 2014-01-01 | ClinicalTrials.gov |
| NCT01566877 | A Study to Assess the Safety, Tolerability and Pharmacokinetics of AVI-7288 in … | Phase1 | Marburg Hemorrhagic Fever | Completed | 2013-05-01 | 2014-01-01 | ClinicalTrials.gov |
| NCT01593072 | A Study to Assess the Safety, Tolerability and Pharmacokinetics of AVI-7537 in … | Phase1 | Ebola Hemorrhagic Fever | Withdrawn | 2012-08-01 | 2013-01-01 | ClinicalTrials.gov |
| NCT01593072 | A Study to Assess the Safety, Tolerability and Pharmacokinetics of AVI-7537 in … | Phase1 | Ebola Hemorrhagic Fever | Withdrawn | 2012-08-01 | 2013-01-01 | ClinicalTrials.gov |
| NCT01540409 | Efficacy, Safety, and Tolerability Rollover Study of Eteplirsen in Subjects Wit… | Phase2 | Duchenne Muscular Dystrophy (DMD) | Completed | 2012-02-27 | 2017-08-16 | ClinicalTrials.gov |
| NCT01540409 | Efficacy, Safety, and Tolerability Rollover Study of Eteplirsen in Subjects Wit… | Phase2 | Duchenne Muscular Dystrophy (DMD) | Completed | 2012-02-27 | 2017-08-16 | ClinicalTrials.gov |
| NCT01396239 | Efficacy Study of AVI-4658 to Induce Dystrophin Expression in Selected Duchenne… | Phase2 | Duchenne Muscular Dystrophy | Completed | 2011-07-01 | 2012-06-01 | ClinicalTrials.gov |
| NCT01396239 | Efficacy Study of AVI-4658 to Induce Dystrophin Expression in Selected Duchenne… | Phase2 | Duchenne Muscular Dystrophy | Completed | 2011-07-01 | 2012-06-01 | ClinicalTrials.gov |
| NCT01375985 | Safety Study of Single Administration Intravenous Treatment for Influenza | Phase1 | Influenza | Terminated | 2011-06-01 | 2011-11-01 | ClinicalTrials.gov |
| NCT01375985 | Safety Study of Single Administration Intravenous Treatment for Influenza | Phase1 | Influenza | Terminated | 2011-06-01 | 2011-11-01 | ClinicalTrials.gov |
| NCT01353040 | Safety Study of Single Administration Post-exposure Prophylaxis Treatment for M… | Phase1 | Marburg Hemorrhagic Fever | Completed | 2011-05-01 | 2011-12-01 | ClinicalTrials.gov |
| NCT01353040 | Safety Study of Single Administration Post-exposure Prophylaxis Treatment for M… | Phase1 | Marburg Hemorrhagic Fever | Completed | 2011-05-01 | 2011-12-01 | ClinicalTrials.gov |
| NCT01353027 | Safety Study of Single Administration Post-Exposure Prophylaxis Treatment for E… | Phase1 | Ebola Hemorrhagic Fever | Completed | 2010-05-01 | 2011-11-01 | ClinicalTrials.gov |
| NCT01353027 | Safety Study of Single Administration Post-Exposure Prophylaxis Treatment for E… | Phase1 | Ebola Hemorrhagic Fever | Completed | 2010-05-01 | 2011-11-01 | ClinicalTrials.gov |
| NCT00844597 | Dose-Ranging Study of AVI-4658 to Induce Dystrophin Expression in Selected Duch… | Phase1 | Duchenne Muscular Dystrophy | Completed | 2009-01-01 | 2010-12-01 | ClinicalTrials.gov |
| NCT00844597 | Dose-Ranging Study of AVI-4658 to Induce Dystrophin Expression in Selected Duch… | Phase1 | Duchenne Muscular Dystrophy | Completed | 2009-01-01 | 2010-12-01 | ClinicalTrials.gov |
| NCT00159250 | Safety and Efficacy Study of Antisense Oligonucleotides in Duchenne Muscular Dy… | Phase1 | Duchenne Muscular Dystrophy | Completed | 2007-10-26 | 2009-03-31 | ClinicalTrials.gov |
| NCT00159250 | Safety and Efficacy Study of Antisense Oligonucleotides in Duchenne Muscular Dy… | Phase1 | Duchenne Muscular Dystrophy | Completed | 2007-10-26 | 2009-03-31 | ClinicalTrials.gov |
| NCT00451256 | Safety and Efficacy Study of AVI-5126 When Used on Vein Grafts Before Use in He… | Phase2 | Cardiovascular Disease | Terminated | 2007-03-01 | 2009-03-01 | ClinicalTrials.gov |
| NCT00451256 | Safety and Efficacy Study of AVI-5126 When Used on Vein Grafts Before Use in He… | Phase2 | Cardiovascular Disease | Terminated | 2007-03-01 | 2009-03-01 | ClinicalTrials.gov |
| NCT00387283 | Pharmacokinetic Study in Cerebral Spinal Fluid After a Single Dose of AVI-4020 | Phase1 | West Nile Virus | Completed | 2006-10-01 | 2009-06-01 | ClinicalTrials.gov |
| NCT00387283 | Pharmacokinetic Study in Cerebral Spinal Fluid After a Single Dose of AVI-4020 | Phase1 | West Nile Virus | Completed | 2006-10-01 | 2009-06-01 | ClinicalTrials.gov |
| NCT00381433 | Pharmacokinetic Study of a Single Dose of AVI-4065 in Cerebral Spinal Fluid | Phase1 | Encephalitis | Completed | 2006-09-01 | 2009-06-01 | ClinicalTrials.gov |
| NCT00381433 | Pharmacokinetic Study of a Single Dose of AVI-4065 in Cerebral Spinal Fluid | Phase1 | Encephalitis | Completed | 2006-09-01 | 2009-06-01 | ClinicalTrials.gov |
| NCT00343148 | Pharmacokinetic Study of a Single Dose of AVI-4126 (RESTEN-NG®) in Cerebral Spi… | Phase1 | Neoplasms | Completed | 2006-06-01 | 2009-06-01 | ClinicalTrials.gov |
| NCT00343148 | Pharmacokinetic Study of a Single Dose of AVI-4126 (RESTEN-NG®) in Cerebral Spi… | Phase1 | Neoplasms | Completed | 2006-06-01 | 2009-06-01 | ClinicalTrials.gov |
| NCT00229749 | Study of AVI-4065 in Healthy Volunteers and Chronic Active HCV Patients | Phase1 | Hepatitis C | Terminated | 2005-09-01 | 2007-01-01 | ClinicalTrials.gov |
| NCT00248066 | Safety and Efficacy of RESTEN-MP When Used in Conjunction With a Bare Metal Ste… | Phase2 | Coronary Artery Disease | Completed | 2005-09-01 | — | ClinicalTrials.gov |
| NCT00248066 | Safety and Efficacy of RESTEN-MP When Used in Conjunction With a Bare Metal Ste… | Phase2 | Coronary Artery Disease | Completed | 2005-09-01 | — | ClinicalTrials.gov |
| NCT00229749 | Study of AVI-4065 in Healthy Volunteers and Chronic Active HCV Patients | Phase1 | Hepatitis C | Terminated | 2005-09-01 | 2007-01-01 | ClinicalTrials.gov |
| NCT00091845 | An Exploratory Study of AVI-4020 in Patients With Possible Acute Neuroinvasive … | Phase1 | West Nile Fever | Terminated | 2004-11-01 | 2004-11-01 | ClinicalTrials.gov |
| NCT00091845 | An Exploratory Study of AVI-4020 in Patients With Possible Acute Neuroinvasive … | Phase1 | West Nile Fever | Terminated | 2004-11-01 | 2004-11-01 | ClinicalTrials.gov |
| NCT00244647 | A Phase 1b Study Evaluating RESTEN-MP in Subjects With Focal de Novo Stenosis | Phase1 | Coronary Artery Disease | Terminated | 2003-08-01 | — | ClinicalTrials.gov |
| NCT00244647 | A Phase 1b Study Evaluating RESTEN-MP in Subjects With Focal de Novo Stenosis | Phase1 | Coronary Artery Disease | Terminated | 2003-08-01 | — | ClinicalTrials.gov |
Total clinical trials: 114
| Product Name | Type | Development Stage | Therapeutic Area | Study Status | Trial ID |
|---|---|---|---|---|---|
| Confirmatory Testing | Other | Preclinical | Spinal Muscular Atrophy | ACTIVE_NOT_RECRUITING | NCT03655223 |
| delandistrogene moxeparvovec | Other | Phase PHASE1 | Duchenne Muscular Dystrophy | RECRUITING | NCT04626674 |
| Placebo | Other | Phase PHASE1 | Huntington's Disease | RECRUITING | NCT07536061 |
| SRP-1005 | Other | Phase PHASE1 | Huntington's Disease | RECRUITING | NCT07536061 |
| Antibiotics | Other | Phase PHASE4 | Duchenne Muscular Dystrophy | NOT_YET_RECRUITING | NCT07542314 |
| Glucocorticoids | Other | Phase PHASE4 | Duchenne Muscular Dystrophy | NOT_YET_RECRUITING | NCT07542314 |
| Sirolimus | Other | Phase PHASE4 | Duchenne Muscular Dystrophy | NOT_YET_RECRUITING | NCT07542314 |
| ELEVIDYS | Other | Phase PHASE4 | Duchenne Muscular Dystrophy | NOT_YET_RECRUITING | NCT07542314 |
| Antibiotics | Other | Phase PHASE4 | Duchenne Muscular Dystrophy | NOT_YET_RECRUITING | NCT07542314 |
| Glucocorticoids | Other | Phase PHASE4 | Duchenne Muscular Dystrophy | NOT_YET_RECRUITING | NCT07542314 |
| Sirolimus | Other | Phase PHASE4 | Duchenne Muscular Dystrophy | NOT_YET_RECRUITING | NCT07542314 |
| ELEVIDYS | Other | Phase PHASE4 | Duchenne Muscular Dystrophy | NOT_YET_RECRUITING | NCT07542314 |
| Antibiotics | Other | Phase PHASE4 | Duchenne Muscular Dystrophy | NOT_YET_RECRUITING | NCT07542314 |
| Glucocorticoids | Other | Phase PHASE4 | Duchenne Muscular Dystrophy | NOT_YET_RECRUITING | NCT07542314 |
| Sirolimus | Other | Phase PHASE4 | Duchenne Muscular Dystrophy | NOT_YET_RECRUITING | NCT07542314 |
| ELEVIDYS | Other | Phase PHASE4 | Duchenne Muscular Dystrophy | NOT_YET_RECRUITING | NCT07542314 |
| Antibiotics | Other | Phase PHASE4 | Duchenne Muscular Dystrophy | NOT_YET_RECRUITING | NCT07542314 |
| Glucocorticoids | Other | Phase PHASE4 | Duchenne Muscular Dystrophy | NOT_YET_RECRUITING | NCT07542314 |
| Sirolimus | Other | Phase PHASE4 | Duchenne Muscular Dystrophy | NOT_YET_RECRUITING | NCT07542314 |
| ELEVIDYS | Other | Phase PHASE4 | Duchenne Muscular Dystrophy | NOT_YET_RECRUITING | NCT07542314 |
| Antibiotics | Other | Phase PHASE4 | Duchenne Muscular Dystrophy | NOT_YET_RECRUITING | NCT07542314 |
| Glucocorticoids | Other | Phase PHASE4 | Duchenne Muscular Dystrophy | NOT_YET_RECRUITING | NCT07542314 |
| Sirolimus | Other | Phase PHASE4 | Duchenne Muscular Dystrophy | NOT_YET_RECRUITING | NCT07542314 |
| ELEVIDYS | Other | Phase PHASE4 | Duchenne Muscular Dystrophy | NOT_YET_RECRUITING | NCT07542314 |
| Antibiotics | Other | Phase PHASE4 | Duchenne Muscular Dystrophy | NOT_YET_RECRUITING | NCT07542314 |
| Glucocorticoids | Other | Phase PHASE4 | Duchenne Muscular Dystrophy | NOT_YET_RECRUITING | NCT07542314 |
| Sirolimus | Other | Phase PHASE4 | Duchenne Muscular Dystrophy | NOT_YET_RECRUITING | NCT07542314 |
| ELEVIDYS | Other | Phase PHASE4 | Duchenne Muscular Dystrophy | NOT_YET_RECRUITING | NCT07542314 |
| Antibiotics | Other | Phase PHASE4 | Duchenne Muscular Dystrophy | NOT_YET_RECRUITING | NCT07542314 |
| Glucocorticoids | Other | Phase PHASE4 | Duchenne Muscular Dystrophy | NOT_YET_RECRUITING | NCT07542314 |
| Sirolimus | Other | Phase PHASE4 | Duchenne Muscular Dystrophy | NOT_YET_RECRUITING | NCT07542314 |
| ELEVIDYS | Other | Phase PHASE4 | Duchenne Muscular Dystrophy | NOT_YET_RECRUITING | NCT07542314 |
| Antibiotics | Other | Phase PHASE4 | Duchenne Muscular Dystrophy | NOT_YET_RECRUITING | NCT07542314 |
| Glucocorticoids | Other | Phase PHASE4 | Duchenne Muscular Dystrophy | NOT_YET_RECRUITING | NCT07542314 |
| Sirolimus | Other | Phase PHASE4 | Duchenne Muscular Dystrophy | NOT_YET_RECRUITING | NCT07542314 |
| ELEVIDYS | Other | Phase PHASE4 | Duchenne Muscular Dystrophy | NOT_YET_RECRUITING | NCT07542314 |
| Antibiotics | Other | Phase PHASE4 | Duchenne Muscular Dystrophy | NOT_YET_RECRUITING | NCT07542314 |
| Glucocorticoids | Other | Phase PHASE4 | Duchenne Muscular Dystrophy | NOT_YET_RECRUITING | NCT07542314 |
| Sirolimus | Other | Phase PHASE4 | Duchenne Muscular Dystrophy | NOT_YET_RECRUITING | NCT07542314 |
| ELEVIDYS | Other | Phase PHASE4 | Duchenne Muscular Dystrophy | NOT_YET_RECRUITING | NCT07542314 |
| Antibiotics | Other | Phase PHASE4 | Duchenne Muscular Dystrophy | NOT_YET_RECRUITING | NCT07542314 |
| Glucocorticoids | Other | Phase PHASE4 | Duchenne Muscular Dystrophy | NOT_YET_RECRUITING | NCT07542314 |
| Sirolimus | Other | Phase PHASE4 | Duchenne Muscular Dystrophy | NOT_YET_RECRUITING | NCT07542314 |
| ELEVIDYS | Other | Phase PHASE4 | Duchenne Muscular Dystrophy | NOT_YET_RECRUITING | NCT07542314 |
| placebo | Other | Phase PHASE3 | Duchenne Muscular Dystrophy | ACTIVE_NOT_RECRUITING | NCT05881408 |
| delandistrogene moxeparvovec | Other | Phase PHASE3 | Duchenne Muscular Dystrophy | ACTIVE_NOT_RECRUITING | NCT05881408 |
| placebo | Other | Phase PHASE3 | Duchenne Muscular Dystrophy | ACTIVE_NOT_RECRUITING | NCT05881408 |
| delandistrogene moxeparvovec | Other | Phase PHASE3 | Duchenne Muscular Dystrophy | ACTIVE_NOT_RECRUITING | NCT05881408 |
| placebo | Other | Phase PHASE3 | Duchenne Muscular Dystrophy | ACTIVE_NOT_RECRUITING | NCT05881408 |
| delandistrogene moxeparvovec | Other | Phase PHASE3 | Duchenne Muscular Dystrophy | ACTIVE_NOT_RECRUITING | NCT05881408 |
| placebo | Other | Phase PHASE3 | Duchenne Muscular Dystrophy | ACTIVE_NOT_RECRUITING | NCT05881408 |
| delandistrogene moxeparvovec | Other | Phase PHASE3 | Duchenne Muscular Dystrophy | ACTIVE_NOT_RECRUITING | NCT05881408 |
| placebo | Other | Phase PHASE3 | Duchenne Muscular Dystrophy | ACTIVE_NOT_RECRUITING | NCT05881408 |
| delandistrogene moxeparvovec | Other | Phase PHASE3 | Duchenne Muscular Dystrophy | ACTIVE_NOT_RECRUITING | NCT05881408 |
| delandistrogene moxeparvovec | Other | Phase PHASE2 | Duchenne Muscular Dystrophy | ACTIVE_NOT_RECRUITING | NCT06128564 |
| delandistrogene moxeparvovec | Other | Phase PHASE2 | Duchenne Muscular Dystrophy | ACTIVE_NOT_RECRUITING | NCT06128564 |
| delandistrogene moxeparvovec | Other | Phase PHASE2 | Duchenne Muscular Dystrophy | ACTIVE_NOT_RECRUITING | NCT06128564 |
| delandistrogene moxeparvovec | Other | Phase PHASE2 | Duchenne Muscular Dystrophy | ACTIVE_NOT_RECRUITING | NCT06128564 |
| delandistrogene moxeparvovec | Other | Phase PHASE2 | Duchenne Muscular Dystrophy | ACTIVE_NOT_RECRUITING | NCT06128564 |
| delandistrogene moxeparvovec | Other | Phase PHASE2 | Duchenne Muscular Dystrophy | ACTIVE_NOT_RECRUITING | NCT06128564 |
| Standard of Care | Other | Preclinical | Duchenne Muscular Dystrophy | ENROLLING_BY_INVITATION | NCT06270719 |
| Delandistrogene Moxeparvovec | Other | Preclinical | Duchenne Muscular Dystrophy | ENROLLING_BY_INVITATION | NCT06270719 |
| Standard of Care | Other | Preclinical | Duchenne Muscular Dystrophy | ENROLLING_BY_INVITATION | NCT06270719 |
| Delandistrogene Moxeparvovec | Other | Preclinical | Duchenne Muscular Dystrophy | ENROLLING_BY_INVITATION | NCT06270719 |
| Standard of Care | Other | Preclinical | Duchenne Muscular Dystrophy | ENROLLING_BY_INVITATION | NCT06270719 |
| Delandistrogene Moxeparvovec | Other | Preclinical | Duchenne Muscular Dystrophy | ENROLLING_BY_INVITATION | NCT06270719 |
| Standard of Care | Other | Preclinical | Duchenne Muscular Dystrophy | ENROLLING_BY_INVITATION | NCT06270719 |
| Delandistrogene Moxeparvovec | Other | Preclinical | Duchenne Muscular Dystrophy | ENROLLING_BY_INVITATION | NCT06270719 |
| Standard of Care | Other | Preclinical | Duchenne Muscular Dystrophy | ENROLLING_BY_INVITATION | NCT06270719 |
| Delandistrogene Moxeparvovec | Other | Preclinical | Duchenne Muscular Dystrophy | ENROLLING_BY_INVITATION | NCT06270719 |
| Standard of Care | Other | Preclinical | Duchenne Muscular Dystrophy | ENROLLING_BY_INVITATION | NCT06270719 |
| Delandistrogene Moxeparvovec | Other | Preclinical | Duchenne Muscular Dystrophy | ENROLLING_BY_INVITATION | NCT06270719 |
| Standard of Care | Other | Preclinical | Duchenne Muscular Dystrophy | ENROLLING_BY_INVITATION | NCT06270719 |
| Delandistrogene Moxeparvovec | Other | Preclinical | Duchenne Muscular Dystrophy | ENROLLING_BY_INVITATION | NCT06270719 |
| Standard of Care | Other | Preclinical | Duchenne Muscular Dystrophy | ENROLLING_BY_INVITATION | NCT06270719 |
| Delandistrogene Moxeparvovec | Other | Preclinical | Duchenne Muscular Dystrophy | ENROLLING_BY_INVITATION | NCT06270719 |
| Standard of Care | Other | Preclinical | Duchenne Muscular Dystrophy | ENROLLING_BY_INVITATION | NCT06270719 |
| Delandistrogene Moxeparvovec | Other | Preclinical | Duchenne Muscular Dystrophy | ENROLLING_BY_INVITATION | NCT06270719 |
| Standard of Care | Other | Preclinical | Duchenne Muscular Dystrophy | ENROLLING_BY_INVITATION | NCT06270719 |
| Delandistrogene Moxeparvovec | Other | Preclinical | Duchenne Muscular Dystrophy | ENROLLING_BY_INVITATION | NCT06270719 |
| Standard of Care | Other | Preclinical | Duchenne Muscular Dystrophy | ENROLLING_BY_INVITATION | NCT06270719 |
| Delandistrogene Moxeparvovec | Other | Preclinical | Duchenne Muscular Dystrophy | ENROLLING_BY_INVITATION | NCT06270719 |
| Corticosteroid | Other | Phase PHASE3 | Muscular Dystrophies, Limb-Girdle | WITHDRAWN | NCT06952686 |
| SRP-9005 | Other | Phase PHASE3 | Muscular Dystrophies, Limb-Girdle | WITHDRAWN | NCT06952686 |
| AVI-6002 | Other | Phase PHASE1 | Ebola Hemorrhagic Fever | COMPLETED | NCT01353027 |
| Placebo | Other | Phase PHASE1 | Ebola Hemorrhagic Fever | COMPLETED | NCT01353027 |
| Placebo | Other | Phase PHASE1 | Marburg Hemorrhagic Fever | COMPLETED | NCT01353040 |
| AVI-6003 | Other | Phase PHASE1 | Marburg Hemorrhagic Fever | COMPLETED | NCT01353040 |
| Normal Saline Solution (NSS) | Other | Phase PHASE1 | Ebola Hemorrhagic Fever | WITHDRAWN | NCT01593072 |
| AVI-7537 | Other | Phase PHASE1 | Ebola Hemorrhagic Fever | WITHDRAWN | NCT01593072 |
| Placebo | Other | Phase PHASE1 | Influenza | TERMINATED | NCT01375985 |
| AVI-7100 | Other | Phase PHASE1 | Influenza | TERMINATED | NCT01375985 |
| Placebo | Other | Phase PHASE1 | Marburg Hemorrhagic Fever | COMPLETED | NCT01566877 |
| AVI-7288 | Other | Phase PHASE1 | Marburg Hemorrhagic Fever | COMPLETED | NCT01566877 |
| Eteplirsen | Other | Phase PHASE2 | Muscular Dystrophy, Duchenne | COMPLETED | NCT02286947 |
| AVI-4658 (Eteplirsen) | Other | Phase PHASE2 | Duchenne Muscular Dystrophy (DMD) | COMPLETED | NCT01540409 |
| Placebo | Other | Phase PHASE2 | Duchenne Muscular Dystrophy | COMPLETED | NCT01396239 |
| AVI-4658 (Eteplirsen) | Other | Phase PHASE2 | Duchenne Muscular Dystrophy | COMPLETED | NCT01396239 |
| SRP-4053 | Other | Phase PHASE1 | Duchenne Muscular Dystrophy | COMPLETED | NCT02310906 |
| Placebo | Other | Phase PHASE1 | Duchenne Muscular Dystrophy | COMPLETED | NCT02310906 |
| eteplirsen | Other | Phase PHASE2 | Duchenne Muscular Dystrophy (DMD) | COMPLETED | NCT02420379 |
| eteplirsen | Other | Phase PHASE3 | Duchenne Muscular Dystrophy (DMD) | COMPLETED | NCT02255552 |
| rAAVrh74.MHCK7.DYSF.DV | Other | Phase PHASE1 | Dysferlinopathy | COMPLETED | NCT02710500 |
| Placebo | Other | Phase PHASE1 | Duchenne Muscular Dystrophy | COMPLETED | NCT02530905 |
| SRP-4045 | Other | Phase PHASE1 | Duchenne Muscular Dystrophy | COMPLETED | NCT02530905 |
| Eteplirsen | Other | Phase PHASE2 | Duchenne Muscular Dystrophy | COMPLETED | NCT03218995 |
| SRP-5051 | Other | Phase PHASE1 | Muscular Dystrophy, Duchenne | COMPLETED | NCT03375255 |
| SRP-9004 | Other | Phase PHASE1 | Limb-Girdle Muscular Dystrophy, Type 2D | COMPLETED | NCT01976091 |
| Eteplirsen | Other | Phase PHASE2 | Duchenne Muscular Dystrophy | TERMINATED | NCT03985878 |
| Vyondys 53 | Other | Phase PHASE2 | Duchenne Muscular Dystrophy | COMPLETED | NCT04179409 |
| Exondys 51 | Other | Phase PHASE2 | Duchenne Muscular Dystrophy | COMPLETED | NCT04179409 |
| Amondys 45 | Other | Phase PHASE2 | Duchenne Muscular Dystrophy | COMPLETED | NCT04179409 |
| Classical conditioning task | Other | Preclinical | DMD | RECRUITING | NCT06581887 |
| SRP-5051 | Other | Phase PHASE1 | Muscular Dystrophy, Duchenne | TERMINATED | NCT03675126 |
| Golodirsen | Other | Phase PHASE3 | Duchenne Muscular Dystrophy | TERMINATED | NCT03532542 |
| Casimersen | Other | Phase PHASE3 | Duchenne Muscular Dystrophy | TERMINATED | NCT03532542 |
| placebo | Other | Phase PHASE1 | Muscular Dystrophy, Duchenne | COMPLETED | NCT03769116 |
| delandistrogene moxeparvovec | Other | Phase PHASE1 | Muscular Dystrophy, Duchenne | COMPLETED | NCT03769116 |
| delandistrogene moxeparvovec | Other | Phase PHASE1 | Duchenne Muscular Dystrophy | COMPLETED | NCT03375164 |
| Vesleteplirsen | Other | Phase PHASE2 | Duchenne Muscular Dystrophy | TERMINATED | NCT04004065 |
| Confirmatory Testing | Other | Preclinical | Spinal Muscular Atrophy | ENROLLING_BY_INVITATION | NCT03655223 |
| placebo | Other | Phase PHASE3 | Duchenne Muscular Dystrophy | ACTIVE_NOT_RECRUITING | NCT05881408 |
| delandistrogene moxeparvovec | Other | Phase PHASE3 | Duchenne Muscular Dystrophy | ACTIVE_NOT_RECRUITING | NCT05881408 |
| placebo | Other | Phase PHASE3 | Duchenne Muscular Dystrophy | COMPLETED | NCT05096221 |
| delandistrogene moxeparvovec | Other | Phase PHASE3 | Duchenne Muscular Dystrophy | COMPLETED | NCT05096221 |
| SRP-9004 | Other | Phase PHASE1 | Limb Girdle Muscular Dystrophy | TERMINATED | NCT06747273 |
| Plasmapheresis | Other | Phase PHASE1 | Duchenne Muscular Dystrophy | TERMINATED | NCT06597656 |
| delandistrogene moxeparvovec | Other | Phase PHASE1 | Duchenne Muscular Dystrophy | TERMINATED | NCT06597656 |
| SRP-6004 | Other | Phase PHASE1 | Limb Girdle Muscular Dystrophy | TERMINATED | NCT05906251 |
| Casimersen | Other | Preclinical | Duchenne Muscular Dystrophy | ENROLLING_BY_INVITATION | NCT06606340 |
| Golodirsen | Other | Preclinical | Duchenne Muscular Dystrophy | ENROLLING_BY_INVITATION | NCT06606340 |
| Eteplirsen | Other | Preclinical | Duchenne Muscular Dystrophy | ENROLLING_BY_INVITATION | NCT06606340 |
| Glucocorticoid | Other | Phase PHASE3 | Limb-girdle Muscular Dystrophy | ACTIVE_NOT_RECRUITING | NCT06246513 |
| SRP-9003 | Other | Phase PHASE3 | Limb-girdle Muscular Dystrophy | ACTIVE_NOT_RECRUITING | NCT06246513 |
| Placebo | Other | Phase PHASE3 | Duchenne Muscular Dystrophy | COMPLETED | NCT02500381 |
| SRP-4053 | Other | Phase PHASE3 | Duchenne Muscular Dystrophy | COMPLETED | NCT02500381 |
| SRP-4045 | Other | Phase PHASE3 | Duchenne Muscular Dystrophy | COMPLETED | NCT02500381 |
| imlifidase | Other | Phase PHASE1 | Duchenne Muscular Dystrophy | TERMINATED | NCT06241950 |
| delandistrogene moxeparvovec | Other | Phase PHASE1 | Duchenne Muscular Dystrophy | TERMINATED | NCT06241950 |
| Standard of Care | Other | Preclinical | Duchenne Muscular Dystrophy | ENROLLING_BY_INVITATION | NCT06270719 |
| Delandistrogene Moxeparvovec | Other | Preclinical | Duchenne Muscular Dystrophy | ENROLLING_BY_INVITATION | NCT06270719 |
| SRP-9003 | Other | Phase PHASE1 | Limb-Girdle Muscular Dystrophy, Type 2E | TERMINATED | NCT03652259 |
| delandistrogene moxeparvovec | Other | Phase PHASE3 | Duchenne Muscular Dystrophy | ENROLLING_BY_INVITATION | NCT05967351 |
| delandistrogene moxeparvovec | Other | Phase PHASE2 | Duchenne Muscular Dystrophy | ACTIVE_NOT_RECRUITING | NCT06128564 |
| SRP-9003 | Other | Phase PHASE1 | Limb Girdle Muscular Dystrophy | ACTIVE_NOT_RECRUITING | NCT05876780 |
| Eteplirsen | Other | Phase PHASE3 | Muscular Dystrophy, Duchenne | ACTIVE_NOT_RECRUITING | NCT03992430 |
| Golodirsen 50 MG/1 ML Intravenous Solution [VYONDYS 53] | Other | Phase PHASE4 | Duchenne Muscular Dystrophy | TERMINATED | NCT04708314 |
| delandistrogene moxeparvovec | Other | Phase PHASE1 | Muscular Dystrophy, Duchenne | RECRUITING | NCT04626674 |
| Antibiotics | Other | Phase PHASE4 | Duchenne Muscular Dystrophy | NOT_YET_RECRUITING | NCT07542314 |
| Glucocorticoids | Other | Phase PHASE4 | Duchenne Muscular Dystrophy | NOT_YET_RECRUITING | NCT07542314 |
| Sirolimus | Other | Phase PHASE4 | Duchenne Muscular Dystrophy | NOT_YET_RECRUITING | NCT07542314 |
| ELEVIDYS | Other | Phase PHASE4 | Duchenne Muscular Dystrophy | NOT_YET_RECRUITING | NCT07542314 |
| Antibiotics | Other | Phase PHASE4 | Duchenne Muscular Dystrophy | NOT_YET_RECRUITING | NCT07542314 |
| Glucocorticoids | Other | Phase PHASE4 | Duchenne Muscular Dystrophy | NOT_YET_RECRUITING | NCT07542314 |
| Sirolimus | Other | Phase PHASE4 | Duchenne Muscular Dystrophy | NOT_YET_RECRUITING | NCT07542314 |
| ELEVIDYS | Other | Phase PHASE4 | Duchenne Muscular Dystrophy | NOT_YET_RECRUITING | NCT07542314 |
| Antibiotics | Other | Phase PHASE4 | Duchenne Muscular Dystrophy | NOT_YET_RECRUITING | NCT07542314 |
| Glucocorticoids | Other | Phase PHASE4 | Duchenne Muscular Dystrophy | NOT_YET_RECRUITING | NCT07542314 |
| Sirolimus | Other | Phase PHASE4 | Duchenne Muscular Dystrophy | NOT_YET_RECRUITING | NCT07542314 |
| ELEVIDYS | Other | Phase PHASE4 | Duchenne Muscular Dystrophy | NOT_YET_RECRUITING | NCT07542314 |
| Antibiotics | Other | Phase PHASE4 | Duchenne Muscular Dystrophy | NOT_YET_RECRUITING | NCT07542314 |
| Glucocorticoids | Other | Phase PHASE4 | Duchenne Muscular Dystrophy | NOT_YET_RECRUITING | NCT07542314 |
| Sirolimus | Other | Phase PHASE4 | Duchenne Muscular Dystrophy | NOT_YET_RECRUITING | NCT07542314 |
| ELEVIDYS | Other | Phase PHASE4 | Duchenne Muscular Dystrophy | NOT_YET_RECRUITING | NCT07542314 |
| Antibiotics | Other | Phase PHASE4 | Duchenne Muscular Dystrophy | NOT_YET_RECRUITING | NCT07542314 |
| Glucocorticoids | Other | Phase PHASE4 | Duchenne Muscular Dystrophy | NOT_YET_RECRUITING | NCT07542314 |
| Sirolimus | Other | Phase PHASE4 | Duchenne Muscular Dystrophy | NOT_YET_RECRUITING | NCT07542314 |
| ELEVIDYS | Other | Phase PHASE4 | Duchenne Muscular Dystrophy | NOT_YET_RECRUITING | NCT07542314 |
| Antibiotics | Other | Phase PHASE4 | Duchenne Muscular Dystrophy | NOT_YET_RECRUITING | NCT07542314 |
| Glucocorticoids | Other | Phase PHASE4 | Duchenne Muscular Dystrophy | NOT_YET_RECRUITING | NCT07542314 |
| Sirolimus | Other | Phase PHASE4 | Duchenne Muscular Dystrophy | NOT_YET_RECRUITING | NCT07542314 |
| ELEVIDYS | Other | Phase PHASE4 | Duchenne Muscular Dystrophy | NOT_YET_RECRUITING | NCT07542314 |
| Antibiotics | Other | Phase PHASE4 | Duchenne Muscular Dystrophy | NOT_YET_RECRUITING | NCT07542314 |
| Glucocorticoids | Other | Phase PHASE4 | Duchenne Muscular Dystrophy | NOT_YET_RECRUITING | NCT07542314 |
| Sirolimus | Other | Phase PHASE4 | Duchenne Muscular Dystrophy | NOT_YET_RECRUITING | NCT07542314 |
| ELEVIDYS | Other | Phase PHASE4 | Duchenne Muscular Dystrophy | NOT_YET_RECRUITING | NCT07542314 |
| Antibiotics | Other | Phase PHASE4 | Duchenne Muscular Dystrophy | NOT_YET_RECRUITING | NCT07542314 |
| Glucocorticoids | Other | Phase PHASE4 | Duchenne Muscular Dystrophy | NOT_YET_RECRUITING | NCT07542314 |
| Sirolimus | Other | Phase PHASE4 | Duchenne Muscular Dystrophy | NOT_YET_RECRUITING | NCT07542314 |
| ELEVIDYS | Other | Phase PHASE4 | Duchenne Muscular Dystrophy | NOT_YET_RECRUITING | NCT07542314 |
| Antibiotics | Other | Phase PHASE4 | Duchenne Muscular Dystrophy | NOT_YET_RECRUITING | NCT07542314 |
| Glucocorticoids | Other | Phase PHASE4 | Duchenne Muscular Dystrophy | NOT_YET_RECRUITING | NCT07542314 |
| Sirolimus | Other | Phase PHASE4 | Duchenne Muscular Dystrophy | NOT_YET_RECRUITING | NCT07542314 |
| ELEVIDYS | Other | Phase PHASE4 | Duchenne Muscular Dystrophy | NOT_YET_RECRUITING | NCT07542314 |
| Placebo | Other | Phase PHASE1 | Huntington's Disease | NOT_YET_RECRUITING | NCT07536061 |
| SRP-1005 | Other | Phase PHASE1 | Huntington's Disease | NOT_YET_RECRUITING | NCT07536061 |
| Corticosteroid | DRUG | Phase PHASE3 | Muscular Dystrophies, Limb-Girdle | WITHDRAWN | NCT06952686 |
| SRP-9005 | BIOLOGICAL | Phase PHASE3 | Muscular Dystrophies, Limb-Girdle | WITHDRAWN | NCT06952686 |
| Plasmapheresis | PROCEDURE | Phase PHASE1 | Duchenne Muscular Dystrophy | TERMINATED | NCT06597656 |
| Classical conditioning task | BEHAVIORAL | Preclinical | DMD | RECRUITING | NCT06581887 |
| Standard of Care | DRUG | Preclinical | Duchenne Muscular Dystrophy | ENROLLING_BY_INVITATION | NCT06270719 |
| Delandistrogene Moxeparvovec | GENETIC | Preclinical | Duchenne Muscular Dystrophy | ENROLLING_BY_INVITATION | NCT06270719 |
| Glucocorticoid | DRUG | Phase PHASE3 | Limb-girdle Muscular Dystrophy | ACTIVE_NOT_RECRUITING | NCT06246513 |
| imlifidase | BIOLOGICAL | Phase PHASE1 | Duchenne Muscular Dystrophy | TERMINATED | NCT06241950 |
| SRP-6004 | GENETIC | Phase PHASE1 | Limb Girdle Muscular Dystrophy | TERMINATED | NCT05906251 |
| Golodirsen 50 MG/1 ML Intravenous Solution [VYONDYS 53] | DRUG | Phase PHASE4 | Duchenne Muscular Dystrophy | TERMINATED | NCT04708314 |
| Vyondys 53 | DRUG | Phase PHASE2 | Duchenne Muscular Dystrophy | COMPLETED | NCT04179409 |
| Exondys 51 | DRUG | Phase PHASE2 | Duchenne Muscular Dystrophy | COMPLETED | NCT04179409 |
| Amondys 45 | DRUG | Phase PHASE2 | Duchenne Muscular Dystrophy | COMPLETED | NCT04179409 |
| Vesleteplirsen | DRUG | Phase PHASE2 | Duchenne Muscular Dystrophy | TERMINATED | NCT04004065 |
| placebo | GENETIC | Phase PHASE3 | Duchenne Muscular Dystrophy | ACTIVE_NOT_RECRUITING | NCT05881408 |
| SRP-9003 | BIOLOGICAL | Phase PHASE3 | Limb-girdle Muscular Dystrophy | ACTIVE_NOT_RECRUITING | NCT06246513 |
| Golodirsen | DRUG | Preclinical | Duchenne Muscular Dystrophy | ENROLLING_BY_INVITATION | NCT06606340 |
| Casimersen | DRUG | Preclinical | Duchenne Muscular Dystrophy | ENROLLING_BY_INVITATION | NCT06606340 |
| SRP-5051 | DRUG | Phase PHASE1 | Muscular Dystrophy, Duchenne | TERMINATED | NCT03675126 |
| delandistrogene moxeparvovec | GENETIC | Phase PHASE1 | Duchenne Muscular Dystrophy | TERMINATED | NCT06597656 |
| rAAVrh74.MHCK7.DYSF.DV | DRUG | Phase PHASE1 | Dysferlinopathy | COMPLETED | NCT02710500 |
| SRP-4045 | DRUG | Phase PHASE1 | Duchenne Muscular Dystrophy | COMPLETED | NCT02530905 |
| SRP-4053 | DRUG | Phase PHASE3 | Duchenne Muscular Dystrophy | COMPLETED | NCT02500381 |
| Eteplirsen | DRUG | Preclinical | Duchenne Muscular Dystrophy | ENROLLING_BY_INVITATION | NCT06606340 |
| eteplirsen | DRUG | Phase PHASE2 | Duchenne Muscular Dystrophy (DMD) | COMPLETED | NCT02420379 |
| Normal Saline Solution (NSS) | OTHER | Phase PHASE1 | Ebola Hemorrhagic Fever | WITHDRAWN | NCT01593072 |
| AVI-7537 | DRUG | Phase PHASE1 | Ebola Hemorrhagic Fever | WITHDRAWN | NCT01593072 |
| AVI-7100 | DRUG | Phase PHASE1 | Influenza | TERMINATED | NCT01375985 |
| SRP-9004 | DRUG | Phase PHASE1 | Limb Girdle Muscular Dystrophy | TERMINATED | NCT06747273 |
| AVI-7288 | DRUG | Phase PHASE1 | Marburg Hemorrhagic Fever | COMPLETED | NCT01566877 |
| AVI-4658 (Eteplirsen) | DRUG | Phase PHASE2 | Duchenne Muscular Dystrophy (DMD) | COMPLETED | NCT01540409 |
| AVI-6003 | DRUG | Phase PHASE1 | Marburg Hemorrhagic Fever | COMPLETED | NCT01353040 |
| AVI-6002 | DRUG | Phase PHASE1 | Ebola Hemorrhagic Fever | COMPLETED | NCT01353027 |
| Placebo | DRUG | Phase PHASE1 | Duchenne Muscular Dystrophy | COMPLETED | NCT02530905 |
| AVI-4658 for Injection | DRUG | Phase PHASE1 | Duchenne Muscular Dystrophy | COMPLETED | NCT00844597 |
| AVI-5126 | DRUG | Phase PHASE2 | Cardiovascular Disease | TERMINATED | NCT00451256 |
| AVI-4065 Injection | DRUG | Phase PHASE1 | Encephalitis | COMPLETED | NCT00381433 |
| AVI-4126 Injection (RESTEN-NG®) | DRUG | Phase PHASE1 | Neoplasms | COMPLETED | NCT00343148 |
| RESTEN-MP | DRUG | Phase PHASE2 | Coronary Artery Disease | COMPLETED | NCT00248066 |
| AVI-4658 (PMO) | DRUG | Phase PHASE1 | Duchenne Muscular Dystrophy | COMPLETED | NCT00159250 |
| AVI-4020 Injection | DRUG | Phase PHASE1 | West Nile Virus | COMPLETED | NCT00387283 |
Total products: 227